Back in November, as Allergan was reeling from the news that it could face earlier-than-expected copies of its blockbuster eye drug Restasis, CEO Brent Saunders promised investors that cost cuts were ...

Allergan's ($AGN) pulled back the veil on the restructuring it's hoping will lure shareholders away from Valeant's ($VRX) $53 billion hostile buyout bid. Among the ...

Allergan Inc. said it will cut about 1,500 jobs over the remainder of this year as part of a restructuring plan to save about $475 million next year. The Business Journal last week reported that the ...

July 21 (Reuters) - Allergan Inc, which is fighting a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday it would cut 13 percent of its workforce as part of a restructuring ...

Allergan will eliminate more than 1,000 positions in anticipation of generic competition surrounding its popular dry-eye drug Restasis, reports Bloomberg. 1. Allergan CEO Brent Saunders hinted at the ...